Dr. Gary Remington, MD, PhD
Claim this profileCentre for Addiction and Mental Health
Studies Schizophrenia
Studies High Risk for Psychosis
2 reported clinical trials
3 drugs studied
Affiliated Hospitals
Clinical Trials Gary Remington, MD, PhD is currently running
Extended Antipsychotic Dosing
for Schizophrenia
The study wishes to examine whether "extended" antipsychotic treatment, in this case, antipsychotic treatment every other day, is as effective as daily treatment. It is also evaluating whether there may be differences in terms of side effects. Participants will be randomly assigned to either the treatment as usual group (i.e., taking antipsychotic daily) or the extended dosing group (i.e., taking antipsychotic one day on, one day off). That means, like flipping a coin, there is a 50/50 chance that participants will continue on daily dosing of your antipsychotic or have it switched to every other day dosing. This study will last for 1 year. Participants will be evaluated at the beginning and every two weeks during the first 6 months, with visits once every 4 weeks for the final 6 months. In total, participants will make 22 visits over 52 weeks to the investigator's office. The investigators hypothesize that with ED, there will be no change in symptom severity but improvement in the frequency and severity of side effects, wellbeing, and functioning.
Recruiting3 awards Phase 47 criteria
Once-Daily vs Twice-Daily Clozapine
for Schizophrenia
Plasma half-life has routinely been used to establish the dosing schedule of antipsychotics; for example, it is recommended that agents with a short plasma half-life be administered multiple times per day. However, to date, several randomized controlled trials (RCTs) have shown no differences in clinical outcomes between once- and twice-daily dosing of various antipsychotics, suggesting that once-daily dosing of antipsychotics is a viable option regardless of plasma half-life. This would apply to clozapine as well; however, there have been no studies comparing once-daily vs. twice-daily dosing regimens of clozapine in terms of efficacy and tolerability. To address this gap in the literature, the investigators shall conduct a pilot, double-blind, RCT to examine efficacy and tolerability following a switch to once-daily dosing regimen of clozapine in patients with schizophrenia receiving clozapine twice a day.
Recruiting3 awards Phase 4
More about Gary Remington, MD, PhD
Clinical Trial Related2 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Gary Remington, MD, PhD has experience with
- Switching From Twice-Daily To Once-Daily Clozapine Dosing
- Olanzapine
- Risperidone
Breakdown of trials Gary Remington, MD, PhD has run
Schizophrenia
High Risk for Psychosis
Schizoaffective Disorder
Drug Therapy
Drug Administration Schedule
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gary Remington, MD, PhD specialize in?
Gary Remington, MD, PhD focuses on Schizophrenia and High Risk for Psychosis. In particular, much of their work with Schizophrenia has involved treating patients, or patients who are undergoing treatment.
Is Gary Remington, MD, PhD currently recruiting for clinical trials?
Yes, Gary Remington, MD, PhD is currently recruiting for 2 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Gary Remington, MD, PhD has studied deeply?
Yes, Gary Remington, MD, PhD has studied treatments such as Switching From Twice-Daily to Once-Daily Clozapine Dosing, Olanzapine, Risperidone.
What is the best way to schedule an appointment with Gary Remington, MD, PhD?
Apply for one of the trials that Gary Remington, MD, PhD is conducting.
What is the office address of Gary Remington, MD, PhD?
The office of Gary Remington, MD, PhD is located at: Centre for Addiction and Mental Health, Toronto, Ontario M5T 1R8 Canada. This is the address for their practice at the Centre for Addiction and Mental Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.